curcumin + vorinostat + sorafenib

This is an experimental three-drug combination consisting of the dietary polyphenol curcumin, the histone deacetylase inhibitor vorinostat, and the multikinase inhibitor sorafenib, evaluated primarily in advanced solid tumors. Sorafenib inhibits RAF kinases (CRAF, BRAF, mutant BRAF) and multiple receptor tyrosine kinases including VEGFR-1/2/3 and PDGFR-β, blocking tumor proliferation via RAF/MEK/ERK signaling and tumor angiogenesis via VEGFR/PDGFR signaling[1][3][6][10]. Vorinostat (suberoylanilide hydroxamic acid) is an epigenetic modulator that inhibits histone deacetylases, and has been clinically tested with sorafenib; in a phase 1 study in unresectable hepatocellular carcinoma, adding vorinostat to sorafenib required frequent dose modifications due to toxicities and was not recommended for further exploration with that schedule[4]. Curcumin is a natural compound with preclinical evidence of sensitizing hepatocellular carcinoma cells to sorafenib-induced cell cycle arrest and apoptosis, suggesting potential synergy[2]. A registered pilot dose-escalation clinical trial specifically studied the combination of curcumin, vorinostat, and sorafenib to determine the highest tolerable dose in patients with advanced solid tumors[7][9].

Other names

curcumin vorinostat sorafenib combination